The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2024

Filed:

Feb. 15, 2021
Applicants:

The Hong Kong University of Science and Technology, Hong Kong, CN;

The Government of the United States of America As Represented BY the Secretary of the Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Nancy Yuk-Yu Ip, Hong Kong, CN;

Kit Yu Fu, Hong Kong, CN;

Wing Yu Fu, Hong Kong, CN;

Dimiter S. Dimitrov, Frederick, MD (US);

Tianlei Ying, Frederick, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 25/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 39/39558 (2013.01); A61P 25/28 (2018.01); A61P 35/00 (2018.01); C07K 14/71 (2013.01); G01N 33/57492 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides new, fully human EphA4 monoclonal antibodies with distinct binding characteristics. Also disclosed are antigen binding fragments of these antibodies, bispecific forms of these antibodies, and conjugates of these antibodies. In addition, nucleic acids encoding these antibodies, antigen binding fragments, bispecific antibodies and conjugates are disclosed. These monoclonal antibodies, antigen binding fragments, bispecific antibodies, conjugates, nucleic acids and vector are of use for identifying and treating a subject with a disease or condition involving abnormal EphA4-mediated signaling.


Find Patent Forward Citations

Loading…